



## Novel Insights into Radiopharmaceutics for Cancer Therapy

Guest Editors:

### Dr. Clément Morgat

1. Department of Nuclear  
Medicine, University Hospital of  
Bordeaux, F-33000 Bordeaux,  
France  
2. INCIA, Translational Molecular  
Imaging Team, University of  
Bordeaux, F-33000 Bordeaux,  
France

### Dr. David Kryza

Laboratoire d'Automatique, de  
Génie des Procédés et de Génie  
Pharmaceutique, Université  
Claude Bernard Lyon 1, CNRS  
UMR 5007, 43 bd 11 Novembre  
1918, 69622 Villeurbanne, France

Deadline for manuscript  
submissions:

**closed (31 March 2022)**

### Message from the Guest Editors

Dear Colleagues,

Targeted radionuclide therapy (TRT) has reached the culmination of translational research with the pivotal NETTER and VISION trials. Patients suffering from metastatic neuroendocrine tumors and metastatic prostate cancer tumors now benefit from this new treatment modality in our departments. However, we should continue and intensify preclinical and clinical research to determine the best place of TRT throughout the various progressive stages of cancer. We should also focus our efforts on deciphering treatment resistance and recurrence mechanisms but also testing novel combinations and dose regimens for targeted radio-/immuno-/chemotherapies. Finally, the design of novel radiopharmaceuticals armed with innovative radionuclides for TRT or for pretherapeutic imaging or radiopharmaceuticals targeting novel molecular signatures of cancer cells might expand the applications of TRT to diseases not currently eligible for TRT and would increase the efficacy of TRT.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

Pharmaceutics Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma